MIT Develops Biodegradable “Smart Pill” to Track Medication Adherence

By Bio-IT World News Staff 

March 4, 2026 | Medication nonadherence has long been one of healthcare’s most stubborn problems. Roughly half of patients with chronic conditions do not take their medications as prescribed, according to the World Health Organization. This problem undermines treatment, fuels drug resistance, and costs the U.S. healthcare system hundreds of billions of dollars each year. However, engineers at MIT might be able to offer a new way forward. 

In a recent proof-of-concept study published in Nature Communications (DOI: 10.1038/s41467-025-67551-5), researchers describe an ingestible, bioresorbable RFID-based sensor system called SAFARI, designed to confirm—safely and reliably—that a patient has actually swallowed a pill. Unlike earlier “smart pill” approaches, SAFARI is built almost entirely from biodegradable materials, addressing both patient safety and environmental concerns. 

At the core of the technology is a clever materials-science solution to a basic engineering problem: how to ensure that an ingestible sensor only transmits a signal once it has been swallowed. The team solved this by developing two key device technologies. The first is a biodegradable Faraday cage made with cellulose and trace metals such as molybdenum or tungsten. Before ingestion, the coating blocks all radiofrequency signals. Once inside the gastrointestinal tract, it degrades, simultaneously releasing the medication and activating a bioresorbable RFID antenna that signals successful ingestion. The second is a miniature RFID tag housing a microchip that generates the ingestion signal and can be incorporated into standard pill capsules. Communication confirming ingestion occurs within about 10 minutes, and short-term animal studies show that the metals used fall within FDA-recognized safe ranges and are cleared from the body over several days. 

In practice, SAFARI would pair with a wearable RFID receiver—potentially embedded in a necklace—that captures signals from the stomach and transmits the data to a secure cloud system. Clinicians could then identify missed doses and intervene with targeted, confidential conversations, rather than relying on self-reporting or pharmacy refill data. 

Beyond clinical care, the platform addresses a persistent limitation of earlier ingestible electronics, which often rely on rigid, non-degradable components that are excreted intact, raising safety and environmental concerns. By contrast, SAFARI represents one of the first large-animal demonstrations of a fully bioresorbable ingestible sensor system. 

To read the full story written by Deborah Borfitz, head over to Clinical Research News.